Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of DUOFAG for bacterial infections in complicated skin wounds
2025-522752-45-00Phase 3Authorised
- Sponsor
- MB Pharma
- Start
- Feb 2026
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Wound infection (WI), surgical site infection (SSI), secondarily infected traumatic lesion (SITL) and 2 more comparing DUOFAG arm with Placebo arm (2 arms). Primary endpoints: Safety (serious adverse reactions/events during IMP administration phase), Efficiency (1) presence of S. aureus and/or P. aeruginosa colonies and 1 more. Planned start Feb 2026; status: authorised.
02
Drugs
DUOFAG
03
Conditions
Wound infection (WI)surgical site infection (SSI)secondarily infected traumatic lesion (SITL)Staphylococcus aureus infectionPseudomonal infection
Beyond the preview
Go deeper on 2025-522752-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522752-45-00.